Understanding urothelial carcinoma through cancer pathways

Urothelial carcinoma (UC), the common histological subtype of bladder cancer, presents as a papillary tumor or as an invasive, often lethal form. To study UC molecular biology, candidate gene and genome‐wide approaches have been followed. Here, it is argued that a ‘cancer pathway’ perspective is useful to integrate findings from both approaches. According to this view, papillary cancers typically exhibit activation of the MAPK pathway, as a consequence of oncogenic mutations in FGFR3 or HRAS, with increased Cyclin D1 expression. In contrast, invasive UC are characterized by severe disturbances in proximate cell cycle regulators, e.g. RB1 and CDKN2A/p16INK4A, which decrease dependency on mitogenic signaling. In addition, these disturbances permit, promote and are in turn exacerbated by chromosomal instability, which is further enhanced by loss of TP53 function. In another vicious cycle, defective cell cycle regulation interacts with DNA methylation alterations. The transition toward invasive UC may require concomitant and interacting defects in cell cycle regulation and the control of genomic stability. Intriguingly, neither canonical WNT/β‐Catenin nor hedgehog signaling appear to play major roles in UC. This may reflect its origin from more differentiated urothelial cells possessing a high regenerative potential rather than a stem cell population. © 2006 Wiley‐Liss, Inc.

[1]  W. Schulz,et al.  Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer , 2005, Molecular Cancer.

[2]  Adel H Jebar,et al.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma , 2005, Oncogene.

[3]  F. Schliess,et al.  Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. , 2003, Experimental cell research.

[4]  R. Millikan,et al.  Focus on bladder cancer. , 2004, Cancer cell.

[5]  David M. Berman,et al.  Tissue repair and stem cell renewal in carcinogenesis , 2004, Nature.

[6]  W. Schulz,et al.  Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines. , 2000, Cancer research.

[7]  R. Dahiya,et al.  Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer. , 2002, The Journal of urology.

[8]  T. Sun,et al.  Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation , 2001, Oncogene.

[9]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[10]  H. von der Maase,et al.  Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. , 2002, Journal of the National Cancer Institute.

[11]  M. Knowles,et al.  Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma , 2001, Oncogene.

[12]  F. Rousseau,et al.  Alteration of the PATCHED locus in superficial bladder cancer , 2003, Oncogene.

[13]  Ekaterini Blaveri,et al.  Bladder cancer outcome and subtype classification by gene expression. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  W. Schulz,et al.  E-cadherin involved in inactivation of WNT/β-catenin signalling in urothelial carcinoma and normal urothelial cells , 2003, British Journal of Cancer.

[15]  H. Moch,et al.  Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer , 2002, Oncogene.

[16]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[17]  Ishtiaq Rehman,et al.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Knowles,et al.  Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype , 2005, Clinical Cancer Research.

[19]  S. Groshen,et al.  Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Wallerand,et al.  FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.

[21]  P. Hamilton,et al.  Molecular pathology of non-invasive urothelial carcinomas (part I) , 2003, Virchows Archiv.

[22]  W. Schulz,et al.  Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. , 2000, Urology.

[23]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[24]  Bai-Lin Wu,et al.  High Intensity ras Signaling Induces Premature Senescence by Activating p38 Pathway in Primary Human Fibroblasts* , 2004, Journal of Biological Chemistry.

[25]  W. Schulz,et al.  Over‐expression and amplification of the c‐myc gene in human urothelial carcinoma , 1999, International journal of cancer.

[26]  Christian Pilarsky,et al.  Gene Expression Profiling of Progressive Papillary Noninvasive Carcinomas of the Urinary Bladder , 2005, Clinical Cancer Research.

[27]  T. Ratliff CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. , 2005, Journal of Urology.

[28]  W. Schulz,et al.  Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. , 1998, British Journal of Cancer.

[29]  M. Knowles,et al.  What we could do now: molecular pathology of bladder cancer , 2001, Molecular pathology : MP.

[30]  Rolf Ackermann,et al.  Identifying Superficial, Muscle-Invasive, and Metastasizing Transitional Cell Carcinoma of the Bladder , 2004, Clinical Cancer Research.

[31]  C. Pilarsky,et al.  No evidence for involvement of beta-catenin and APC in urothelial carcinomas. , 2002, International journal of oncology.

[32]  K. Shigeno,et al.  Human bladder tumors with 2-hit mutations of tumor suppressor gene TSC1 and decreased expression of p27. , 2003, The Journal of urology.

[33]  L. Kiemeney,et al.  CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer , 2004, Nature Medicine.

[34]  M. Knowles,et al.  Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. , 2003, Cancer research.

[35]  J. Cairns,et al.  Allelotype of human bladder cancer. , 1994, Cancer research.

[36]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[37]  T. H. van der Kwast,et al.  The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. , 2001, Cancer research.

[38]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[39]  W. Schulz,et al.  Multiple mechanisms downregulate CDKN1C in human bladder cancer , 2005, International journal of cancer.

[40]  Jennifer Southgate,et al.  Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. , 2005, Experimental cell research.

[41]  D. Ornstein Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs , 2004 .

[42]  P. Carroll,et al.  Genetic alterations in primary bladder cancers and their metastases. , 1998, Cancer research.

[43]  D. Chopin,et al.  Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas , 1999, Nature Genetics.

[44]  R. Löwer,et al.  DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas , 1999, British Journal of Cancer.

[45]  R. Weinberg,et al.  Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene , 1982, Nature.

[46]  Wen-Lin Kuo,et al.  Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. , 2003, Cancer research.

[47]  Xue-Ru Wu Urothelial tumorigenesis: a tale of divergent pathways , 2005, Nature Reviews Cancer.

[48]  E. Messing,et al.  DBCCR1 mediates death in cultured bladder tumor cells , 2004, Oncogene.

[49]  W. Schulz,et al.  DNA Methylation and the Mechanisms of CDKN2A Inactivation in Transitional Cell Carcinoma of the Urinary Bladder , 2000, Laboratory Investigation.

[50]  M. Wolter,et al.  Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines , 2005, Journal of cellular physiology.

[51]  R. Wooster,et al.  Amplification and overexpression of E2F3 in human bladder cancer , 2004, Oncogene.

[52]  T. Sun,et al.  Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. , 1999, Cancer research.

[53]  G. Sauter,et al.  E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer , 2004, Oncogene.

[54]  W. Schulz,et al.  Decrease of DNA methyltransferase 1 expression relative to cell proliferation in transitional cell carcinoma , 2003, International journal of cancer.

[55]  M. Knowles,et al.  Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer , 2001, Oncogene.

[56]  I. Gromova,et al.  Impact of proteomics on bladder cancer research. , 2004, Pharmacogenomics.

[57]  N. Malats,et al.  P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.